Healthcare AI Company Rebrands as Rocket Doctor AI to Pursue Growing Market Opportunities
Treatment.com AI Inc. has rebranded and reincorporated as Rocket Doctor AI (AIDR:CSE; TREIF:OTC; 939:FRA) to reflect the integration of its proprietary AI-driven Global Library of Medicine (GLM) with the recently acquired Rocket Doctor Inc. Read why one analyst calls part of the company's offerings "Shopify for physicians." This article is issued on behalf of Rocket Doctor AI AI Healthcare Stock Showing Signs of a Base Breakout
Contributed Opinion John Newell of John Newell & Associates explains why he thinks Rocket Doctor AI (AIDR:CSE; TREIF:OTC; 939:FRA) is a Speculative Buy.
Co.'s Graphene Used in New Screening Test for Lung Cancer
HydroGraph Clean Power Inc.'s (HG:CSE; HGRAF:OTCQB; M98:FSE) patented, high-purity material has applications in healthcare, as in this case, but also in numerous other industries. Read on to learn why some experts say this company could be a future 100-bagger.Medical Co.'s New Joint Venture Could Expand Co.'s Footprint
Research Report
Leede Financial Inc. analyst Dr. Douglas Loe gave this company a Buy rating. Canadian Pharmaceutical Company Discovers Breakthrough Cardiovascular Treatment
Clinical-stage life sciences company Cardiol Therapeutics (CRDL:TSX; CRDL:NASDAQ) announces topline results from its Phase II clinical study involving patients with acute myocarditis. Read why analysts like this pharmaceutical stock.Pharmaceutical Company Discovers Breakthrough Heart Treatment in Canada
Research Report
Top-line results from Cardiol Therapeutics' (CRDL:TSX; CRDL:NASDAQ) ARCHER study for Acute Myocarditis are quite promising, writes Roth Capital Partners Analyst Jason Wittes in an updated research note. Biotech Announces Topline Results From Cardiovascular Drug Trial
Research Report
Cardiol Therapeutics (CRDL:TSX; CRDL:NASDAQ) Analyst Brandon Folkes reviews Cardiol Therapeutics Inc. after it announced the topline results from its Phase II ARCHER trial of CardiolRx in acute myocarditis. Canadian Pharma Finds Promising Cardiovascular Breakthrough
Research Report
Cardiol Therapeutics (CRDL:TSX; CRDL:NASDAQ) reports headline Phase II data from its 109-patient acute myocarditis study, known as the ARCHER trial. Read to see how one analyst rates the stock. Cleantech/Life Sciences Co. Advances Products in Q2/25
Research Report
BioLargo Inc. (BLGO:OTCQX) enters into several agreements, forms partnerships and receives third party product validation, noted an Oak Ridge Financial report. Clean Tech Firm Making Important PFAS Breakthrough
Clean technology company BioLargo Inc. (BLGO:OTCQX) president and chief executive office shares a mid-year update on the company's achievements so far this year, along with insights into its future prospects through a letter to shareholders.Cancer Drug Developer Finds Potent Hits With AI in British Columbia
Rakovina Therapeutics Inc. (RKV:TSX.V) taps machine learning to zero in on novel cancer therapies. Read more about the AI engine driving this high-stakes discovery.Pancreas Cancer Becoming Top Focus for Biotech Co.?
Research Report
Oncolytics Biotech Inc. (ONCY:NASDAQ; ONC:TSX) published survival data for the use of its immunotherapy pelareorep in pancreatic cancer, and these support the view that this indication should be primary, noted a Leede Financial Inc. report. Biotech Firm Clears Major U.S. Trading Hurdle
Rakovina Therapeutics Inc. (RKV:TSX.V) just gained DTC eligibility, opening the door for faster U.S. trades and broader investor access. With AI-driven cancer drugs in development, analysts are taking notice. Read more to find out why.Biotech Partnership to Revolutionize Diabetes Treatment
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) announces a collaborative research agreement with Eledon Pharmaceuticals Inc. to assess Eledon's immunosuppressive drug in Sernova's ongoing trials of its cell pouch biohybrid organ for patients with Type 1 diabetes (T1D).Biotech Enters Agreement with Co. Behind Tegoprubart
Research Report
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) likely will use this new monoclonal antibody as an immunosuppressant in its Phase 1/2 trial's Cohort C instead of previously used tacrolimus, noted an H.C. Wainwright & Co. report.